The authors explored the efficacy of four therapies (anti-TNF-α, anti-PDGF, anti-IL13, anti-TGF-β) and showed that only targeting TGF-β should result in a beneficial effect on pulmonary fibrosis. This evidence concerns the gene IL13 and pulmonary fibrosis.